Article
Veterinary Sciences
L. Muscatello, F. Gobbo, E. Di Oto, G. Sarli, R. De Maria, A. De Leo, G. Tallini, B. Brunetti
Summary: HER2 amplification was found in a subgroup of canine mammary carcinomas, with the HER2 gene copy number correlated with HER2 protein overexpression but not with tumor behavior. Additionally, a possible translocation of HER2/CRYBA1 was discovered. This study highlights the potential for different amplification patterns in studying HER2 in canine mammary tumors.
VETERINARY SCIENCES
(2022)
Review
Nanoscience & Nanotechnology
Chonggao Wang, Yewei Zhang
Summary: Anaplastic thyroid carcinomas (ATCs) are a rare subtype of thyroid cancers with high invasiveness and fatality. A comprehensive individualized therapeutic strategy involving surgery, radiotherapy, chemotherapy, and immunotherapy is preferred. Nanoparticle drug delivery systems have shown potential in the treatment of ATCs.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2023)
Article
Medical Laboratory Technology
De-hui Qiao, Xue-mei He, Xian Deng, Yi-chi Ji, Hui Yang, Lian Cheng, Xiang-yu Zhou
Summary: The study identified aberrant expression of miR-1296-5p, miR-1301-3p, miR-532-5p, miR-551b-3p, and miR-455-3p in papillary thyroid carcinomas, which were associated with clinicopathological features. These five miRNAs show potential diagnostic value according to ROC curve analysis.
JOURNAL OF CLINICAL LABORATORY ANALYSIS
(2021)
Article
Oncology
Mariana Pires Teixeira, Natalia Ferreira Haddad, Eliza Freitas Passos, Marcelle Novaes Andrade, Maria Luisa Arantes Campos, Joyle Moreira Carvalho da Silva, Camila Saggioro de Figueiredo, Elizabeth Giestal-de-Araujo, Denise Pires de Carvalho, Leandro Miranda-Alves, Luciana Souza de Paiva
Summary: In this study, the effects of ouabain on human anaplastic thyroid carcinoma cells were evaluated. The results showed that ouabain may reduce the viability and migratory ability of 8505C cells by inhibiting proliferation. However, the treated cells still maintained an aggressive and undifferentiated profile.
Article
Oncology
Arnaud Jannin, Alexandre Escande, Abir Al Ghuzlan, Pierre Blanchard, Dana Hartl, Benjamin Chevalier, Frederic Deschamps, Livia Lamartina, Ludovic Lacroix, Corinne Dupuy, Eric Baudin, Christine Do Cao, Julien Hadoux
Summary: Anaplastic thyroid carcinoma (ATC) is a rare and aggressive form of thyroid cancer with a poor prognosis. Improving the management of this deadly disease involves the use of molecular tests for targeted therapies, fast-track dedicated care pathways, and prompt initiation of treatment. Adjuvant chemo-radiotherapy is recommended for localized disease after surgery, while chemotherapy or targeted therapy combined with decompressive cervical radiotherapy is recommended for locally advanced or metastatic disease.
Article
Endocrinology & Metabolism
Keith C. Bible, Electron Kebebew, James Brierley, Juan P. Brito, Maria E. Cabanillas, Thomas J. Clark, Antonio Di Cristofano, Robert Foote, Thomas Giordano, Jan Kasperbauer, Kate Newbold, Yuri E. Nikiforov, Gregory Randolph, M. Sara Rosenthal, Anna M. Sawka, Manisha Shah, Ashok Shaha, Robert Smallridge, Carol K. Wong-Clark
Summary: The guidelines for the management of anaplastic thyroid cancer (ATC) aim to provide evidence-based recommendations to inform clinical decision-making, encompassing diagnosis, treatment goals, locoregional and advanced disease approaches, palliative care, surveillance, and ethical considerations.
Article
Medicine, Research & Experimental
Lina Lu, Jennifer Rui Wang, Ying C. Henderson, Shanshan Bai, Jie Yang, Min Hu, Cheng-Kai Shiau, Timothy Pan, Yuanqing Yan, Tuan M. Tran, Jianzhuo Li, Rachel Kieser, Xiao Zhao, Jiping Wang, Roza Nurieva, Michelle D. Williams, Maria E. Cabanillas, Ramona Dadu, Naifa Lamki Busaidy, Mark Zafereo, Nicholas Navin, Stephen Y. Lai, Ruli Gao
Summary: We investigated the transformation process of anaplastic thyroid cancer (ATC) from different subtypes of thyroid cancer using single-cell transcriptomic and genetic alteration data. The transformation included stress-responsive, inflammatory, mitotic-defective, and mesenchymal ATC cells. We identified important milestones including diploid and aneuploid stages, with corresponding phenotypic changes and interactions with other cell types, providing new therapeutic opportunities for ATC treatment.
JOURNAL OF CLINICAL INVESTIGATION
(2023)
Review
Endocrinology & Metabolism
Vincent Cracolici, Nicole A. Cipriani
Summary: Poorly differentiated thyroid carcinoma (PDTC) and high-grade differentiated thyroid carcinoma (HGDTC) are high-grade follicular-derived thyroid carcinomas with intermediate prognosis. They share similar characteristics such as invasion, thyroid follicular-cell origin, and increased mitoses. PDTC must possess certain growth patterns and lack certain nuclear features, while HGDTC can have various architectural and nuclear morphologies. These carcinomas often present with metastases or wide local invasion and may require targeted chemotherapy due to resistance to radioactive iodine. Early recognition of high-grade features is important for patient prognosis and guiding treatment.
ENDOCRINE PATHOLOGY
(2023)
Article
Endocrinology & Metabolism
Sarika N. Rao, Robert C. Smallridge
Summary: Anaplastic thyroid cancer (ATC) is a highly malignant cancer with a low survival rate, especially in older women. It spreads rapidly to nearby structures and distant sites outside the neck. Despite the introduction of newer treatment strategies, further research is needed to improve survival outcomes.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Cell Biology
Marco De Martino, Simona Pellecchia, Francesco Esposito, Federica Liotti, Sara Carmela Credendino, Nella Prevete, Myriam Decaussin-Petrucci, Paolo Chieffi, Gabriella De Vita, Rosa Marina Melillo, Alfredo Fusco, Pierlorenzo Pallante
Summary: Thyroid cancer is a common endocrine malignancy with differentiated and undifferentiated types. Long non-coding RNAs (lncRNAs) have been found to play important regulatory roles in developmental processes and their aberrant expression is associated with cancer. In particular, the lncRNA RMST is downregulated in anaplastic thyroid carcinoma (ATC), while its related protein SOX2 is upregulated. Restoring RMST expression in ATC cells can suppress cell growth, migration, and stemness properties. These findings highlight the critical role of RMST downregulation in ATC development.
CELL DEATH DISCOVERY
(2023)
Article
Oncology
Li-Hsien Wu, Christian R. Pangilinan, Che-Hsin Lee
Summary: Thyroid cancer is the most common endocrine malignancy, and Salmonella can inhibit the growth of anaplastic thyroid cancer by activating the autophagy signaling pathway.
Article
Cell Biology
Jianing Tang, Yongwen Luo, Liang Xiao
Summary: This study identified USP26 as a deubiquitinating enzyme for TAZ in anaplastic thyroid cancer (ATC) and demonstrated its significant influence on cell proliferation, migration, and invasion in ATC. Depletion of USP26 resulted in decreased TAZ protein level and affected the expression of TAZ/TEAD target genes in ATC.
CELL DEATH & DISEASE
(2022)
Article
Chemistry, Multidisciplinary
Qinglin Li, Lizhuo Zhang, Jiayan Lang, Zhuo Tan, Qingqing Feng, Fei Zhu, Guangna Liu, Zhangguo Ying, Xuefei Yu, He Feng, Heqing Yi, Qingliang Wen, Tiefeng Jin, Keman Cheng, Xiao Zhao, Minghua Ge
Summary: This research developed a new nanoparticle (LPm NP) that efficiently delivers mRNA to increase NIS expression in anaplastic thyroid cancer (ATC) cells. In vivo studies show that intratumoral injection of NIS mRNA formulated in optimized LPm NP significantly increases NIS expression in ATC tumor tissue, resulting in increased iodine 131 accumulation and significant inhibition of tumor growth.
Article
Oncology
Sara P. Ginzberg, Julia A. Gasior, Jesse E. Passman, Jacqueline M. Soegaard Ballester, Caitlin B. Finn, Giorgos C. Karakousis, Rachel R. Kelz, Heather Wachtel
Summary: Disparities in the presentation and treatment of anaplastic thyroid cancer (ATC) exist by sex and race/ethnicity, which may reflect differences in access to care and patient and provider preferences. Although survival is similarly poor across groups, efforts should be made to address the potential exacerbation of disparities due to the changing landscape of treatments for ATC.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Miguel A. Zaballos, Adrian Acuna-Ruiz, Marta Morante, Garcilaso Riesco-Eizaguirre, Piero Crespo, Pilar Santisteban
Summary: The study demonstrates that BRAF- and RAS-mutant thyroid cells respond differently to DEL-22379, which cannot be explained by the previously described mechanism of action of the inhibitor. Nonetheless, DEL-22379 exhibits significant anti-tumor effects against BRAF-mutant cells in vivo, while the anti-tumor effects are mild for RAS-mutant cells.
CELLULAR AND MOLECULAR LIFE SCIENCES
(2022)